3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
3
Phase 3
1
Status
Recruiting
3
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
2
Study Type
Interventional
4
Sponsor
Cancer Type
Breast
4
Sarcoma
1
Gynecologic
1
CNS
1
Conditions
Breast Neoplasms
3
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Interventions
Fulvestrant
83
Letrozole
77
Paclitaxel
76
pembrolizumab
72
Specimen Handling
66
Trastuzumab
62
Carboplatin
57
Magnetic Resonance Spectroscopy
51
ribociclib
49
Capecitabine
48
Anastrozole
47
pertuzumab
46
palbociclib
43
exemestane
40
abemaciclib
40
Cyclophosphamide
40
Tamoxifen
39
Biopsy
38
Docetaxel
30
trastuzumab deruxtecan
29
Taxes
28
Radiotherapy
28
Gemcitabine
25
Blood Specimen Collection
25
130-nm albumin-bound paclitaxel
25
olaparib
22
Surveys and Questionnaires
22
Standard of Care
22
sacituzumab govitecan
20
eribulin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
RAD1901
×
Breast
×
90 days
×
Clear all
NCT05386108
2026-06-04
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2
Recruiting
73 enrolled
NCT07198724
2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2
Recruiting
65 enrolled
NCT06382948
2026-04-03
ADELA
MedSIR
Phase 3
Recruiting
240 enrolled
NCT05963997
2026-03-23
SUMIT-ELA
Carrick Therapeutics Limited
Phase 1/2
Completed
49 enrolled